Mavrilimumab
Based on 1 Customer Validation
Mavrilimumab (CAM 3001) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. GM-CSF might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 98.37%
- CAS 番号: 1085337-57-0
- 分子量:143.168 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
Human IgG4 lambda
Human
CSF2Ra/GM-CSFRa/CD116
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cynomolgus monkey models[2]
-
Dosage:3-100 mg/kg
-
Administration:iv, once a week for at least 11 weeks
-
Result:Produced foam cells in the lungs.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 lambda2
ELISA, FACS, Functional assay
-
Loaded Mavrilimumab on AHC2 biosensor, can bind GM-CSF R alpha Protein, Human (HEK293, His, HY-P7783) with an affinity constant of 7.867E-10 M as determined in BLI assay. -
Flow Cytometry analysis of Hela cells labelling GM-CSFRa (red) with Mavrilimumab (anti-GM-CSFRa) (HY-P99031). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG4 (S228P) lambda1(HY-P99987). Black-Unlabelled control, cells without incubation with primary antibody.
化学情報
-
CAS 番号 1085337-57-0
-
性状 Liquid
-
分子量 143.168 kDa
-
Color Colorless to light yellow
-
SMILES
[Mavrilimumab]
-
別名
CAM 3001
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (259 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Paul C Cremer, et al. Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Rheumatol. 2021 Jun;3(6):e410-e41 [Content Brief]
[2]. Ryan PC, et al., Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: relevance for human safety. Toxicol Appl Pharmacol. 2014 Sep 1;279(2):230-9. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)